Adecatumumab: an anti-EpCAM monoclonal antibody, from the bench to the bedside.
about
Liver cancer stem cell markers: Progression and therapeutic implicationsCancer stem cells and immunoresistance: clinical implications and solutionsCirculating and disseminated tumor cells: diagnostic tools and therapeutic targets in motionNuclear and cytoplasmic accumulation of Ep-ICD is frequently detected in human epithelial cancers.Predicting targeted drug combinations based on Pareto optimal patterns of coexpression network connectivityEpcam, CD44, and CD49f distinguish sphere-forming human prostate basal cells from a subpopulation with predominant tubule initiation capability.Phage displayed peptides/antibodies recognizing growth factors and their tyrosine kinase receptors as tools for anti-cancer therapeutics.The trifunctional antibody catumaxomab in treatment of malignant ascites and peritoneal carcinomatosis.Novel therapeutic strategies for targeting liver cancer stem cells.An anti-EpCAM antibody EpAb2-6 for the treatment of colon cancer.Label-free quantitative proteomics of CD133-positive liver cancer stem cellsRole of the EpCAM (CD326) in prostate cancer metastasis and progression.Cancerous ovarian stem cells: obscure targets for therapy but relevant to chemoresistance.Epithelial cell adhesion molecule-targeted drug delivery for cancer therapy.Cancer stem cells: biological functions and therapeutically targeting.Epithelial cell adhesion molecule-positive human hepatic neoplastic cells: development of combined hepatocellular-cholangiocarcinoma in mice.Liver cancer stem cells are selectively enriched by low-dose cisplatin.Cancer Stem Cells in Hepatocellular Carcinoma.The impact of EpCAM expression on response to chemotherapy and clinical outcomes in patients with epithelial ovarian cancer.The overexpression of epithelial cell adhesion molecule (EpCAM) in glioma.A Single Tri-Epitopic Antibody Virtually Recapitulates the Potency of a Combination of Three Monoclonal Antibodies in Neutralization of Botulinum Neurotoxin Serotype A.Surface markers of liver cancer stem cells and innovative targeted-therapy strategies for HCC.Transcriptional profiling of mouse B cell terminal differentiation defines a signature for antibody-secreting plasma cells.Epithelial cell adhesion molecule (EpCAM) is involved in prostate cancer chemotherapy/radiotherapy response in vivo
P2860
Q26751026-8EFC715C-072C-445C-BEF7-D5C58CF808C8Q26769757-C19C4042-2409-4068-B064-078F21B7589DQ28066285-EB285C98-DD7B-49F2-A80A-D069B6B5E125Q33770286-7200EDFF-4E5A-484D-B986-4E3A9EE9B367Q33772585-799F6ADD-2188-42F5-9121-8995F5C6068BQ34238517-B413085D-40C4-4DCE-8308-BF0F4911287BQ34273411-E3A173D5-9F40-42B2-823E-A7066B06FE1FQ34624096-950C2064-4266-449A-AC73-E65DA278FDB5Q34940971-72E38667-AB6F-4EE6-9D30-90C68F11498AQ36413078-FC0D557A-C782-4293-83ED-178955C06F94Q36621286-26002D9E-5C55-4311-B13D-2EA1C868E0A1Q38020426-9965BE99-7976-4282-A9D3-37B90DBBBF6BQ38034167-DE266A96-8062-47BD-ABF1-39FB93AAB07FQ38073792-64EDE98C-1EF5-4782-8FEA-EB9150944EDAQ38211401-F9A6B5E8-8BA4-44D9-9C39-A4A0FFEBBB9DQ38969232-A3F59D3D-3A61-40EE-B7DA-0B1C52750442Q39000927-5F66458B-8AF7-483E-BA83-EC0D4831E32BQ39393146-7FA9BC43-26D7-4D72-8110-F49DAA974B1BQ41279960-BF7B8855-D4A4-438D-8EE0-FC5424E2ED56Q48729015-F959084F-8D7A-464B-9500-57A653855EEDQ49805666-27607A2D-F542-4935-95F9-16BE7750212DQ50053655-61A76267-8798-4BB6-8288-6851608C1D3DQ50927930-D6D55800-0F91-410B-A2C3-6BD443D7B8F3Q59136173-24833192-CC23-403A-851B-5C397C8CE1D3
P2860
Adecatumumab: an anti-EpCAM monoclonal antibody, from the bench to the bedside.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on June 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Adecatumumab: an anti-EpCAM monoclonal antibody, from the bench to the bedside.
@en
Adecatumumab: an anti-EpCAM monoclonal antibody, from the bench to the bedside.
@nl
type
label
Adecatumumab: an anti-EpCAM monoclonal antibody, from the bench to the bedside.
@en
Adecatumumab: an anti-EpCAM monoclonal antibody, from the bench to the bedside.
@nl
prefLabel
Adecatumumab: an anti-EpCAM monoclonal antibody, from the bench to the bedside.
@en
Adecatumumab: an anti-EpCAM monoclonal antibody, from the bench to the bedside.
@nl
P2860
P1476
Adecatumumab: an anti-EpCAM monoclonal antibody, from the bench to the bedside.
@en
P2093
Jean-Emmanuel Kurtz
Patrick Dufour
P2860
P304
P356
10.1517/14712598.2010.482098
P407
P577
2010-06-01T00:00:00Z